AR105653A1 - Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana - Google Patents

Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana

Info

Publication number
AR105653A1
AR105653A1 ARP160102438A ARP160102438A AR105653A1 AR 105653 A1 AR105653 A1 AR 105653A1 AR P160102438 A ARP160102438 A AR P160102438A AR P160102438 A ARP160102438 A AR P160102438A AR 105653 A1 AR105653 A1 AR 105653A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
bencil
piridin
tetrahydroisoquinolin
Prior art date
Application number
ARP160102438A
Other languages
English (en)
Original Assignee
VIIV HEALTHCARE UK (Nº 5) LTD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56851651&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR105653(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by VIIV HEALTHCARE UK (Nº 5) LTD filed Critical VIIV HEALTHCARE UK (Nº 5) LTD
Publication of AR105653A1 publication Critical patent/AR105653A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un compuesto de fórmula (1), en la que: R¹ está seleccionado de hidrógeno, alquilo o cicloalquilo; R² está seleccionado de tetrahidroisoquinolinilo y está sustituido con 1 sustituyente R⁶ y también con 0 - 3 sustituyentes halo o alquilo; R³ está seleccionado de azetidinilo, pirrolidinilo, piperidinilo, piperazinilo, morfolinilo, homopiperidinilo, homopiperazinilo u homomorfolinilo, y está sustituido con 0 - 3 sustituyentes seleccionados de ciano, halo, alquilo, haloalquilo, alcoxi y haloalcoxi; R⁴ está seleccionado de alquilo o haloalquilo; R⁵ es alquilo; R⁶ está seleccionado de Ar¹, (Ar¹)alquilo, (cromanil)alquilo, cianocicloalquilo o (dihidrobenzodioxinil)alquilo; y Ar¹ es fenilo sustituido con 0 - 5 sustituyentes seleccionados de ciano, halo, alquilo, cicloalquilo, haloalquilo, hidroxi, alcoxi, haloalcoxi, (hidroxi)alcoxi, (alcoxi)alcoxi, fenoxi, benciloxi, carboxi, fenilo y cianocicloalquilo; o una sal farmacéuticamente aceptable del mismo.
ARP160102438A 2015-08-11 2016-08-09 Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana AR105653A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562203791P 2015-08-11 2015-08-11

Publications (1)

Publication Number Publication Date
AR105653A1 true AR105653A1 (es) 2017-10-25

Family

ID=56851651

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102438A AR105653A1 (es) 2015-08-11 2016-08-09 Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana

Country Status (23)

Country Link
US (2) US10189816B2 (es)
EP (1) EP3334716A1 (es)
JP (1) JP6782766B2 (es)
KR (1) KR20180032649A (es)
CN (1) CN108137534A (es)
AR (1) AR105653A1 (es)
AU (1) AU2016306089B2 (es)
CA (1) CA2994791A1 (es)
CL (1) CL2018000363A1 (es)
CO (1) CO2018001359A2 (es)
CR (1) CR20180091A (es)
DO (1) DOP2018000035A (es)
EA (1) EA033057B1 (es)
HK (1) HK1249503A1 (es)
IL (1) IL257240B (es)
MA (1) MA42614A (es)
MX (1) MX2018001722A (es)
PE (1) PE20181002A1 (es)
PH (1) PH12018500294A1 (es)
TW (1) TWI657086B (es)
UA (1) UA120464C2 (es)
WO (1) WO2017025917A1 (es)
ZA (1) ZA201800689B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201718537A (zh) * 2015-08-12 2017-06-01 Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物
US10577353B2 (en) * 2015-08-12 2020-03-03 VIIV Healthcare UK (No.5) Limited 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
US20190152957A1 (en) * 2016-05-11 2019-05-23 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3455217A1 (en) * 2016-05-11 2019-03-20 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
US10407410B2 (en) 2016-05-11 2019-09-10 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3565810A1 (en) * 2017-01-03 2019-11-13 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3565809A1 (en) * 2017-01-03 2019-11-13 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
PT2220076E (pt) 2007-11-15 2012-04-26 Gilead Sciences Inc Inibidores da replicação do vírus da imunodeficiência humana
CN102124011A (zh) 2007-11-15 2011-07-13 贝林格尔.英格海姆国际有限公司 人类免疫缺陷病毒复制的抑制剂
JP5269087B2 (ja) 2007-11-16 2013-08-21 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルス複製のインヒビター
JP5285709B2 (ja) 2007-11-16 2013-09-11 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスの複製阻害薬
US8338441B2 (en) * 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
KR101483834B1 (ko) 2009-12-23 2015-01-16 카트호리이케 유니버시타이트 로이펜 항바이러스 화합물
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
JP2016512511A (ja) 2013-03-13 2016-04-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヒト免疫不全ウイルス複製の阻害剤
ES2623904T3 (es) 2013-03-14 2017-07-12 VIIV Healthcare UK (No.5) Limited Inhibidores de la replicación del virus de la inmunodeficiencia humana
US9193720B2 (en) 2014-02-20 2015-11-24 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3116880B1 (en) 2014-02-20 2018-03-21 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid macrocycles as inhibitors of human immunodeficiency virus replication
TW201718537A (zh) * 2015-08-12 2017-06-01 Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物
US10577353B2 (en) * 2015-08-12 2020-03-03 VIIV Healthcare UK (No.5) Limited 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
KR20180035916A (ko) * 2015-08-12 2018-04-06 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제로서 5-(n-융합된 트리사이클릭 아릴 테트라하이드로이소퀴놀린-6-일) 피리딘-3-일 아세트산 유도체

Also Published As

Publication number Publication date
EA201890361A1 (ru) 2018-11-30
CO2018001359A2 (es) 2018-05-10
US20190092754A1 (en) 2019-03-28
JP6782766B2 (ja) 2020-11-11
DOP2018000035A (es) 2018-03-30
MX2018001722A (es) 2018-05-16
IL257240A (en) 2018-03-29
TW201718549A (zh) 2017-06-01
AU2016306089B2 (en) 2018-08-09
KR20180032649A (ko) 2018-03-30
EP3334716A1 (en) 2018-06-20
US20180230129A1 (en) 2018-08-16
UA120464C2 (uk) 2019-12-10
CL2018000363A1 (es) 2018-07-06
HK1249503A1 (zh) 2018-11-02
MA42614A (fr) 2021-05-26
EA033057B1 (ru) 2019-08-30
US10189816B2 (en) 2019-01-29
IL257240B (en) 2020-02-27
PH12018500294A1 (en) 2018-08-13
CN108137534A (zh) 2018-06-08
ZA201800689B (en) 2021-08-25
JP2018522927A (ja) 2018-08-16
TWI657086B (zh) 2019-04-21
CA2994791A1 (en) 2017-02-16
AU2016306089A1 (en) 2018-03-01
WO2017025917A1 (en) 2017-02-16
PE20181002A1 (es) 2018-06-26
CR20180091A (es) 2018-06-13

Similar Documents

Publication Publication Date Title
AR105653A1 (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
AR099511A1 (es) Derivados del ácido piridin-3-ilacético como inhibidores de la replicación del virus de inmunodeficiencia humana
AR108745A1 (es) Derivados de oxadiazol microbiocidas
MX2019000123A (es) Derivados de 1,3-dihidroxi-fenilo utiles como inmunomoduladores.
AR108388A2 (es) Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas
MX2022008434A (es) Herbicidas de piridazinona.
AR105665A1 (es) Derivados del ácido piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
AR094314A1 (es) Inhibidores de fosfatidilinositol 3-cinasa
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR095721A1 (es) Derivados de piridina
PE20170939A1 (es) Pirimidinonas como inhibidores del factor xia
CR20140057A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-etoxi-etil}-1h-[1,2,4]triazol sustituidos
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
MX2019012945A (es) Formas cristalinas de un compuesto inhibidor de jak.
AR116283A1 (es) Inhibidores del sarcómero cardíaco
AR096152A1 (es) Derivados de purina
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR102539A1 (es) Triazolo[4,5-d]pirimidinas
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
AR104512A1 (es) Compuestos de pirazol inhibidores de proteína activadora de 5-lipoxigenasa (flap)
AR100439A1 (es) Derivados de carboxamida
ES2571577T3 (es) Derivados novedosos de morfolinilo útiles como inhibidores de MOGAT-2

Legal Events

Date Code Title Description
FB Suspension of granting procedure